Cargando…

Clinical Efficacy and Safety of Fanhdi(®), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study

OBJECTIVE: To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. METHODS: A retrospective, multicentric, observational study of VWD patients treated with F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiménez-Yuste, Víctor, Alvarez-Román, María Teresa, Palomo Bravo, Ángeles, Galmes, Bernardo J., Nieto Hernández, Maria del Mar, Benítez Hidalgo, Olga, Marzo Alonso, Cristina, Pérez González, Noelia Florencia, Coll, Julia, Núñez, Ramiro, Carrasco, Marina, García Candel, Faustino, Gonzalez-Porras, Jose Ramon, Hernández García, Carmen, Varó Castro, Maria José, Mir, Roser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814963/ https://www.ncbi.nlm.nih.gov/pubmed/35108125 http://dx.doi.org/10.1177/10760296221074348

Ejemplares similares

Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
por: De Padua, Valeria, et al.
Publicado: (2020)

Efficacy and safety evaluation of Fanhdi(®), a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study
por: Jimenez‐Yuste, Victor, et al.
Publicado: (2021)

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project
por: Pérez-Rodríguez, Almudena, et al.
Publicado: (2018)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Recent Findings on Platelet Activation, vWF Multimers and Other Thrombotic Biomarkers Associated with Critical COVID-19
por: Damián-Vázquez, Guadalupe, et al.
Publicado: (2022)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events
por: Warlo, Ellen M. K., et al.
Publicado: (2022)

Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review
por: Sun, Shawn X., et al.
Publicado: (2023)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

The Cost of Von Willebrand Disease in Europe: The CVESS Study
por: Morgan, George, et al.
Publicado: (2022)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
por: Lissitchkov, Toshko, et al.
Publicado: (2020)

In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor
por: Colling, Meaghan E., et al.
Publicado: (2019)

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Von Willebrand disease type 2B with a novel mutation in the VWF gene
por: Jeraiby, Mohammed Abdullah, et al.
Publicado: (2021)

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA
por: Borràs, Nina, et al.
Publicado: (2019)

Von Willebrand Disease in Older Patients: A Retrospective Electronic Health Record Review
por: Seaman, Craig D.
Publicado: (2022)

Polyphosphate Activates von Willebrand Factor Interaction with Glycoprotein Ib in the Absence of Factor VIII In Vitro
por: Montilla, Marcela, et al.
Publicado: (2022)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene
por: Sadler, Brooke, et al.
Publicado: (2021)

Burden of Illness and Treatment Patterns Among Patients With von Willebrand Disease in US Clinical Practice
por: Swallow, Elyse, et al.
Publicado: (2023)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

VIII International Meeting on Lorentzian Geometry
por: Cañadas-Pinedo, María, et al.
Publicado: (2017)

Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions
por: Casari, Caterina, et al.
Publicado: (2013)

von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis
por: Wang, Q., et al.
Publicado: (2020)

Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension
por: Myllylahti, Lasse, et al.
Publicado: (2023)

Subcellular platelet factor VIII antigen and von Willebrand factor
Publicado: (1975)

The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V
por: Pablo-Moreno, Juan A. De, et al.
Publicado: (2022)

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
por: Hatayama, Yuki, et al.
Publicado: (2022)

Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
por: Rugeri, Lucia, et al.
Publicado: (2022)

Disease Burden in Patients with von Willebrand Disease Potentially Eligible for Prophylaxis: Post Hoc Analysis of a European Cross-Sectional Study
por: Du, Ping, et al.
Publicado: (2022)

How to keep the factor VIII/von Willebrand factor complex in the circulation
por: Denis, Cécile V., et al.
Publicado: (2021)

Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes
por: Parker, Ernest T., et al.
Publicado: (2022)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

Proton Pump Inhibitors and the Risk of Early Aseptic Loosening in Hip and Knee Arthroplasty
por: Tamimi, Iskandar, et al.
Publicado: (2022)

Association of Single Nucleotide Polymorphisms in the ST3GAL4 Gene with VWF Antigen and Factor VIII Activity
por: Song, Jaewoo, et al.
Publicado: (2016)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m6huadfsrpneic49ru8nt7uij4